Skip to main content

Winter Clinical Hawaii, 2025

Filter
Close
Content type:
Bimekizumab efficacy and safety over 48 weeks in US and Canadian patients with psoriasis who had a treatment interruption after 3 years of treatment: Results from BE RADIANT
Lebwohl Mark, Papp Kim, Ehst Benjamin, et al.
Poster
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon B. Kenneth, Thaci Diamant, Gooderham Melinda, et al.
Poster
Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT
Naik B Haley, Daveluy Steven, Errol Prens, et al.
Poster
Bimekizumab efficacy and safety through 2 years in patients with hidradenitis suppurativa: Results from the phase 3 BE HEARD I&II trials and open-label extension BE HEARD EXT
Zouboulis C. Christos, Amit Garg, Christopher J Sayed, et al.
Poster
Bimekizumab 4-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from BE BRIGHT
Merola F. Joseph, Gottlieb B. Alice, Soung Jennifer, et al.
Poster